PLIANT THERAPEUTICS, INC.

Pliant Therapeutics is a biopharmaceutical company focused on discovering and developing small-molecule therapies targeting fibrosis and related diseases. The company's approach centers on selective inhibition of integrin pathways, which play a role in fibrotic disease progression. Its lead candidate, bexotegrast, is an oral dual selective inhibitor of avβ6 and avβ1 integrins that has completed Phase 2a clinical evaluation for primary sclerosing cholangitis, a chronic liver disease characterized by progressive fibrosis of the bile ducts.

The company's pipeline includes multiple integrin-targeted programs at varying stages of development. PLN-1474, an oral selective avβ1 inhibitor, is being developed for liver fibrosis associated with nonalcoholic steatohepatitis. PLN-101095, a dual inhibitor of avβ8 and avβ1 integrins, targets solid tumors. PLN-101325 is a Phase 1-ready program for muscular dystrophies, including Duchenne muscular dystrophy, representing expansion into non-fibrotic indications.

Incorporated in Delaware in 2015, Pliant Therapeutics operates from South San Francisco, California, with approximately 171 full-time employees. The company is publicly traded on Nasdaq. As a clinical-stage biopharmaceutical organization, the company remains dependent on advancement of its pipeline programs and has not yet generated significant commercial revenues.